DB05048ExperimentalSmall molecule
Cannabinor, a synthetic CB2-selective agonist, is in Phase 2 clinical testing as an analgesic.
- Mechanism
- Curator reviewed
CB2 agonists bind to CB2 receptors, which are located on immune and inflammatory cells. By activating CB2 receptors, CB2 agonists inhibit autoimmune and inflammatory processes and are likely to be useful for treating pain, autoimmune and inflammatory disorders. Pharmos is developing its CB2 agonists as treatments for chronic pain and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.
- Primary indication
- Investigated for use/treatment in pain (acute or chronic).Curator reviewed
- Formula / weight
- C28H38O6 · 470.606 g/mol (avg)
- Code names
- PRS-211,375
Resolves to
Structure
InChIKey
GSTZHANFXAKPSE-MXTREEOPSA-NSMILES[H][C@]12C[C@]([H])(C(=O)C[C@@H]1C1=C(O)C=C(C=C1OC(=O)\C=C\C(O)=O)C(C)(C)CCCCCC)C2(C)CTargets
What you can answer from here — as of June 15, 2026
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Cannabinor, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account